Press Releases

InVivo Therapeutics Featured in Nationally Syndicated Radio Segment

Published: January 18, 2017

– Health Expert Lisa Davis Interviews CEO and Chairman Mark Perrin – CAMBRIDGE, Mass. (Jan 18, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin was interviewed by Lisa Davis, M.P.H., C.N.C. for a segment on “It’s Your Health” radio during the annual J.P. Morgan Healthcare Conference. Lisa Davis is the creator, host, and producer of “It’s Your Health” radio, which is heard on NPR affiliate and commercial talk radio stations. The show can also be heard on iHeartRadio Talk, TuneIn, Stitcher, iTunes, UberRadio, and TalkStreamLive. “It’s great to be featured on a show that reaches so […]

View Article
InVivo Therapeutics Announces University of New Mexico Hospital as New Site for INSPIRE Study

Published: January 17, 2017

CAMBRIDGE, Mass. (Jan 17, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of New Mexico Hospital (UNMH) in Albuquerque, NM has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The University of New Mexico Hospital (UNMH) is the state’s only Level I trauma center. “I am pleased to be joining the INSPIRE study and look forward to the opportunity to safely investigate this innovative experimental therapy,” said Jeremy Lewis, M.D., Assistant […]

View Article
InVivo Therapeutics Announces INSPIRE’S 29th Clinical Site: Rhode Island Hospital

Published: January 10, 2017

CAMBRIDGE, Mass. (Jan 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rhode Island Hospital in Providence, RI has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Rhode Island Hospital is the principal teaching hospital of The Warren Alpert Medical School of Brown University and is the designated Level I trauma center for southeastern New England. “My research interests lie in understanding repair and plasticity within the spinal cord. I look forward […]

View Article
InVivo Therapeutics Announces St. Michael’s Hospital as New Canadian Site for INSPIRE Study

Published: January 9, 2017

CAMBRIDGE, Mass. (Jan 9, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the St. Michael’s Hospital has been added as a Canadian clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The St. Michael’s Hospital is InVivo’s second site in Toronto and sees over 70,000 emergency visits annually. “My research focuses on engineering applications to neurosurgical procedures with the goal of improving safety and outcome for patients. The INSPIRE study holds much promise for this large unmet […]

View Article
InVivo Therapeutics Responds to PixarBio Announcement

Published: January 3, 2017

CAMBRIDGE, Mass. (Jan 3, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today issued a response to a PixarBio Corporation press release dated January 3, 2017. The press release claimed that PixarBio had made a $77,000,000 stock offer to acquire InVivo. InVivo Therapeutics Corporation was not privy to the announcement made today and has not had any discussions with PixarBio Corporation nor any other party regarding this matter. Given that the nature of the offer is not credible, InVivo disclaims any obligation to make any additional public statements regarding this or similar proposed transactions from PixarBio. The PixarBio press release contained […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study

Published: December 20, 2016

CAMBRIDGE, Mass. (Dec 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient with a T8-9 fracture dislocation injury has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and a member of the INSPIRE Study Steering Committee, performed the implantation with his partner, Samuel Chewning, M.D. Surgery was performed approximately […]

View Article
InVivo Therapeutics to Present at 2016 Tissue Engineering & Regenerative Medicine International Society Americas Conference

Published: December 12, 2016

CAMBRIDGE, Mass. (Dec 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the abstract “Demonstration of a Proof-of-Concept Device for Delivering Bioengineered Neural Stem Cell Trails to the Spinal Cord” has been accepted for presentation at the 2016 Tissue Engineering & Regenerative Medicine  International  Society  (TERMIS)  Americas  Annual  Conference  and  Exhibition,  to be held December 11-14, 2016 in San Diego, CA. Artem Kutikov, Ph.D., Research Scientist, will be giving the poster presentation. The abstract is co-authored Dr.  Kutikov,  Richard  Layer,  Ph.D.,  Simon  Moore, Ph.D., Alex Aimetti, Ph.D., Christoph Hofstetter, M.D., Ph.D.,  James  Guest,  M.D.,  Ph.D.,  and  Thomas Ulich, […]

View Article
InVivo Therapeutics Appoints Melanie Morel-Ferris, C.P.A. as Interim CFO, Replacing Steven McAllister in Role

Published: December 8, 2016

CAMBRIDGE, Mass. (Dec 8, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the resignation of Steven McAllister from the position of Chief Financial Officer effective December 31, 2016. He has indicated he will be transitioning to a new opportunity at a privately-held medical device company. In connection with his departure, the Company has appointed Melanie Morel-Ferris, C.P.A. to assume the responsibilities and title of interim Chief Financial Officer, effective January 1, 2016. In this capacity, she will serve the role of the Company’s Principal Financial Officer and Principal Accounting Officer. Ms. Morel-Ferris has served as the Company’s Controller since […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study

Published: November 17, 2016

CAMBRIDGE, Mass. (Nov 17, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and  Neurologic Recovery in  Subjects with  Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Ahmed M. Raslan, M.D. and Jason J Chang, M.D.,  Assistant  Professors  of  Neurological  Surgery  and  study  investigators, performed surgery and the implantation on the T9  neurologically  complete  patient  approximately  36 hours after the injury occurred. Mark Perrin, InVivo’s Chief Executive Officer and […]

View Article
InVivo Therapeutics to Present at Neuroscience 2016

Published: November 10, 2016

CAMBRIDGE, Mass. (Nov 10, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) will present data from its ongoing nonclinical study of Neuro-Spinal Scaffold™implantation at Neuroscience 2016, the Society for Neuroscience 46th annual conference November 12-16 in San Diego. The company’s oral presentation entitled “The Neuro-Spinal Scaffold promotes tissue remodeling, axonal sprouting, and Schwann cell myelination following acute spinal cord contusion injury in rats” will be presented by Simon Moore, Ph.D., Director of Research on Monday, November 14 at 2:15 PM (PST) during the Brain and Spinal Cord Injury nanosymposium. “I look forward to sharing these latest Neuro-Spinal Scaffold nonclinical findings with the […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.